Want to take quizzes and track your credits?
Targeted therapies for cancer have changed treatment approaches for several solid tumor malignancies. Analyses of cell-free circulating tumor DNA (ctDNA) enable noninvasive cancer detection and characterization, prediction of treatment response, monitoring of disease relapse, and identification of mechanisms of resistance to targeted therapies. With newer technologies, the sensitivity and specificity of ctDNA detection assays have improved and facilitate a greater role for ctDNA diagnostics in clinical practice (Figure).
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Victor E. Velculescu, MD, PhD, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1550 Orleans St, Room 544, Baltimore, MD 21287 (firstname.lastname@example.org).
Conflict of Interest Diclosures: Both authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Husain reports participation on clinical advisory boards for Foundation Medicine, Abbvie, and AstraZeneca; a grant from Pfizer; and lecture honoraria from Bristol-Myers Squibb, Merck, and AstraZeneca. Dr Velculescu reports scientific advisory board and board of directors membership, stock ownership (subject to certain restrictions under university policy), and being a founder of Personal Genome Diagnostics; and being a member of the Ignyta scientific advisory board. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict of interest policies.
Funding/Support: This work was supported by the following grants (Velculescu): National Institutes of Health (CA121113, CA006973, CA180950), Commonwealth Foundation, Dr Miriam and Sheldon G. Adelson Medical Research Foundation, and SU2C-DCS International Translational Cancer Research Dream Team (Stand Up To Cancer, a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research) (SU2C-AACR-DT1415).
You currently have no searches saved.